[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20013812D0 - Anvendelse av 3-hydroksy-3-metylglutaryl coenzym A reduktase inhibitorer for fremstilling av et medikament for behandling avdiabetisk neuropati - Google Patents

Anvendelse av 3-hydroksy-3-metylglutaryl coenzym A reduktase inhibitorer for fremstilling av et medikament for behandling avdiabetisk neuropati

Info

Publication number
NO20013812D0
NO20013812D0 NO20013812A NO20013812A NO20013812D0 NO 20013812 D0 NO20013812 D0 NO 20013812D0 NO 20013812 A NO20013812 A NO 20013812A NO 20013812 A NO20013812 A NO 20013812A NO 20013812 D0 NO20013812 D0 NO 20013812D0
Authority
NO
Norway
Prior art keywords
hydroxy
drug
manufacture
treatment
reductase inhibitors
Prior art date
Application number
NO20013812A
Other languages
English (en)
Other versions
NO330400B1 (no
NO20013812L (no
Inventor
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Application filed by Univ Aberdeen filed Critical Univ Aberdeen
Publication of NO20013812D0 publication Critical patent/NO20013812D0/no
Publication of NO20013812L publication Critical patent/NO20013812L/no
Publication of NO330400B1 publication Critical patent/NO330400B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20013812A 1999-02-06 2001-08-03 Anvendelse av rosuvastatin for fremstilling av et medikament for behandling av diabetisk neuropati NO330400B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Publications (3)

Publication Number Publication Date
NO20013812D0 true NO20013812D0 (no) 2001-08-03
NO20013812L NO20013812L (no) 2001-10-02
NO330400B1 NO330400B1 (no) 2011-04-04

Family

ID=26315085

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013812A NO330400B1 (no) 1999-02-06 2001-08-03 Anvendelse av rosuvastatin for fremstilling av et medikament for behandling av diabetisk neuropati

Country Status (34)

Country Link
US (4) US6894058B1 (no)
EP (2) EP1897546B1 (no)
JP (3) JP2002536332A (no)
KR (1) KR100699757B1 (no)
CN (1) CN1196488C (no)
AR (1) AR025512A1 (no)
AT (2) ATE485823T1 (no)
AU (1) AU763970B2 (no)
BR (1) BR0007996A (no)
CA (1) CA2368186C (no)
CY (2) CY1106879T1 (no)
CZ (2) CZ302881B6 (no)
DE (2) DE60045168D1 (no)
DK (2) DK1150678T3 (no)
EE (2) EE05556B1 (no)
ES (2) ES2286995T3 (no)
GB (1) GB0001662D0 (no)
HK (2) HK1041223A1 (no)
HU (1) HU227642B1 (no)
IL (3) IL144730A0 (no)
IS (2) IS2793B (no)
MX (1) MXPA01007821A (no)
MY (1) MY138289A (no)
NO (1) NO330400B1 (no)
NZ (3) NZ513061A (no)
PL (1) PL198098B1 (no)
PT (2) PT1150678E (no)
RU (1) RU2239456C2 (no)
SI (2) SI1897546T1 (no)
SK (2) SK287792B6 (no)
TR (1) TR200102229T2 (no)
TW (1) TWI230067B (no)
WO (1) WO2000045818A1 (no)
ZA (1) ZA200105885B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU2001232244A1 (en) * 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Drug comprising combination
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
KR100830018B1 (ko) * 2000-10-12 2008-05-15 닛산 가가쿠 고교 가부시키 가이샤 당뇨병 합병증 예방 및 치료제
WO2002032411A2 (en) * 2000-10-18 2002-04-25 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
CZ20031387A3 (cs) 2000-11-30 2004-04-14 Pfizer Products Inc. Farmaceutický prostředek, kterým je směs agonistů gama-aminomáselné kyseliny a inhibitorů aldózreduktázy
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
WO2003077912A1 (en) * 2002-03-20 2003-09-25 The University Of Queensland Method of treatment and/or prophylaxis
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
AU2004233691B2 (en) 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer
ES2421520T3 (es) * 2003-04-28 2013-09-03 Daiichi Sankyo Co Ltd Potenciador de la producción de adiponectina
US20050014799A1 (en) * 2003-06-20 2005-01-20 Biostratum, Inc. Pyridoxamine for the treatment of diabetic kidney disease
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005033067A1 (en) * 2003-10-07 2005-04-14 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
EA023435B1 (ru) * 2008-09-06 2016-06-30 Бионевия Фармасьютикалс, Инк. Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
IN2014CN04119A (no) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
ATE181830T1 (de) 1992-04-13 1999-07-15 Zeneca Ltd Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU713277B2 (en) 1996-04-05 1999-11-25 Takeda Pharmaceutical Company Limited Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
CZ302893B6 (cs) 2012-01-11
WO2000045818A1 (en) 2000-08-10
ZA200105885B (en) 2002-10-17
IL144730A (en) 2010-12-30
MXPA01007821A (es) 2004-08-19
CA2368186A1 (en) 2000-08-10
CZ302881B6 (cs) 2012-01-04
CY1106879T1 (el) 2012-05-23
IL144730A0 (en) 2002-06-30
EE05621B1 (et) 2013-02-15
BR0007996A (pt) 2001-10-30
PT1897546E (pt) 2010-12-15
US20090186908A1 (en) 2009-07-23
JP2012051898A (ja) 2012-03-15
SK11102001A3 (sk) 2002-05-09
DK1150678T3 (da) 2007-10-08
AU2304700A (en) 2000-08-25
US20050209128A1 (en) 2005-09-22
GB0001662D0 (en) 2000-03-15
US6894058B1 (en) 2005-05-17
SI1897546T1 (sl) 2011-02-28
ES2352803T3 (es) 2011-02-23
NZ513061A (en) 2003-06-30
NZ525419A (en) 2004-12-24
DK1897546T3 (da) 2011-01-17
DE60035575D1 (de) 2007-08-30
DE60045168D1 (de) 2010-12-09
HUP0105138A3 (en) 2002-11-28
JP2002536332A (ja) 2002-10-29
SK287792B6 (sk) 2011-10-04
SK286854B6 (sk) 2009-06-05
NO330400B1 (no) 2011-04-04
ATE485823T1 (de) 2010-11-15
DE60035575T2 (de) 2008-04-03
CA2368186C (en) 2008-06-03
CN1196488C (zh) 2005-04-13
ES2286995T3 (es) 2007-12-16
EP1897546A1 (en) 2008-03-12
PL350312A1 (en) 2002-12-02
AU763970B2 (en) 2003-08-07
EP1150678B1 (en) 2007-07-18
CZ20012806A3 (cs) 2002-02-13
KR20010089635A (ko) 2001-10-06
ATE367162T1 (de) 2007-08-15
TR200102229T2 (tr) 2001-12-21
IS8978A (is) 2011-08-23
PL198098B1 (pl) 2008-05-30
AR025512A1 (es) 2002-12-04
JP2014065718A (ja) 2014-04-17
NO20013812L (no) 2001-10-02
EE05556B1 (et) 2012-08-15
EP1897546B1 (en) 2010-10-27
IS2793B (is) 2012-08-15
IL208330A0 (en) 2010-12-30
HU227642B1 (en) 2011-10-28
SI1150678T1 (sl) 2008-02-29
HK1041223A1 (en) 2002-07-05
EE200100405A (et) 2002-10-15
PT1150678E (pt) 2007-09-14
HUP0105138A2 (hu) 2002-04-29
NZ536433A (en) 2006-08-31
CY1110992T1 (el) 2015-06-11
CN1338937A (zh) 2002-03-06
KR100699757B1 (ko) 2007-03-27
US20120041010A1 (en) 2012-02-16
TWI230067B (en) 2005-04-01
HK1118209A1 (en) 2009-02-06
EE201200015A (et) 2012-10-15
RU2239456C2 (ru) 2004-11-10
EP1150678A1 (en) 2001-11-07
MY138289A (en) 2009-05-29
IS6016A (is) 2001-07-20
IS2820B (is) 2012-12-15

Similar Documents

Publication Publication Date Title
NO20013812D0 (no) Anvendelse av 3-hydroksy-3-metylglutaryl coenzym A reduktase inhibitorer for fremstilling av et medikament for behandling avdiabetisk neuropati
DE60020701D1 (de) Thiazol- und oxazol-derivate und ihre pharmazeutische verwendung
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
NO20021963L (no) Anvendelse av organiske forbindelser av sykdom
NO20020770D0 (no) Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av fedme
DE69925133D1 (de) Pyrrolobenzodiazepine
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
DE60045428D1 (de) Intraluminale Auskleidung
DE60315892D1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
NO20013560D0 (no) Polymorfer av telmisartan, fremgangsmåter for fremstilling derav og anvendelse derav for fremstilling av et medikament
DE59806139D1 (de) Verwendung von Pyrimidinderivaten zur Herstellung eines Arzneimittels zur Prävention von Krebs
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
NO20014133D0 (no) Rokbart produkt
NO20012976L (no) Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament
NO20043483L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
MA27173A1 (fr) Utilisation de 3-phenyl-5-alcoxy-1,3,4-oxdiazol-2-one substituee pour la fabrication de medicaments a effet inhibiteur sur la lipase pancreatique
IL162509A (en) Use of deoxypeganine for the production of a drug for treating clinical depression
PL372697A1 (en) Phosphonates and derivatives thereof as enhancers of the activity of insecticides
FI20030044A (fi) Lääkeannostelijan toiminnan ohjausmenetelmä ja mekanismi sen toteuttamiseksi
EE04871B1 (et) Dekstrasoksaani kasutamine, produkt ja meetod psoriaasi raviks m?eldud ravimi valmistamiseks
AU2003214317A1 (en) Use of a novel class of drugs for the treatment of parasitic diseases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees